explore
Previous article:
Moonlake's readout produced a cash windfall. Risks remain
Next article: Acelyrin, a rare IPO success, stumbles in its first big test
Next article: Acelyrin, a rare IPO success, stumbles in its first big test
leisure time
leisure time
-
Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era
2025-08-28 12:35 -
Will the IRA bring competition to the biologics market?
2025-08-28 11:43 -
FDA proposes changes to key medical devices approval pathway
2025-08-28 11:33 -
A common UTI test for kids haunts adults as a traumatic 'nightmare'
2025-08-28 11:30 -
Advocates call out 'SNL' over stereotypes, errors in sickle cell skit
2025-08-28 11:14 -
Advocates call out 'SNL' over stereotypes, errors in sickle cell skit
2025-08-28 10:19